Next Generation Protein Therapeutics & Bioconjugates Summit is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Pavel Strop, PhD
Senior Director at Bristol-Myers Squibb


Dr. Strop received his Ph.D. from Caltech, where he elucidated mechanism and structures of mechanosensitive ion channels. Afterwards, he moved to Stanford, where he focused on proteins involved in synaptic neurotransmission. In 2008, he joined Rinat-Pfizer's protein engineering department where he developed and applied novel technologies for oncology including bispecifics and site-specific antibody drug conjugates. In 2016, he joined Bristol-Myers Squibb in Redwood city, California where he focuses on engineering next generation immuno-oncology therapeutics. Dr. Strop co-authored over 55 peer-reviewed manuscripts and 13 US patents.

Pavel Strop, PhD's Network

Agenda Sessions

  • Modulating Therapeutic Window Of Antibody Drug Conjugates By Protein Engineering: An Industry Prospective

    , 2:15pm
  • PANEL Discussion: Next Generation ADCs: Where do we go from here?

    , 1:45pm